Tristel PLC, a manufacturer of infection prevention products for hospitals, reported strong financial results for the year ended 30 June 2025, with double-digit revenue growth and increased profitability. Here are the key highlights
**Financial Performance**
* Revenue increased by 11% to £46.5 million, driven by higher sales volumes and price increases.
* Gross margin improved to 81%up from 80% in the previous year.
* Adjusted pre-tax profit rose by 23% to £10.1 million, while reported pre-tax profit increased by 18% to £8.4 million.
* Adjusted earnings per share (EPS) grew by 12% to 17.15p, and basic EPS increased to 13.92p.
* The company maintained a strong cash position, with cash and short-term investments of £12.8 million, and continued to be debt-free.
**Operational Highlights**
* FDA clearance was obtained for Tristel OPH, a high-level disinfectant foam for ophthalmic medical devices.
* Successful insourcing of Trio Wipes Manufacturing resulted in net annual savings of £0.8 million.
* Updated USA standards recognized chlorine dioxide foam as a recommended means of high-level disinfection for medical devices.
* A novel study demonstrated the efficacy of chlorine dioxide against biofilms, published in the Journal of Hospital Infection.
* A 90-day study in partnership with the Mayo Clinic concluded that Tristel ULT is an effective and efficient method for high-level disinfection, offering a safe and easy process.
**Post-Period End Developments**
* Appointment of Anna Wasyl as the new Chief Financial Officer (CFO).
* Launch of Tristel VISICLEAN™, a new ultrasound probe decontamination product.
* Q1 sales of DUO ULT more than doubled compared to H1 2024.
* Strong demand in the US market, with engagement across approximately 200 health systems.
**Strategic Focus**
* Geographical expansion, particularly in North America, with a focus on deepening adoption within existing accounts.
* Broadening clinical influence to establish high-level disinfection as the standard of care.
* Expanding the product portfolio with innovations like VISICLEAN™.
* Scaling and monetizing the 3T digital platform to generate recurring revenues.
* Sharpening the surface disinfection strategy around high-value, efficacy-driven hospital environments.
**Dividend and Shareholder Returns**
* Dividend per share increased by 5% to 14.20p, reflecting the companys strong cash generation and commitment to shareholder returns.
Overall, Tristel PLC demonstrated robust financial and operational performance, with a clear strategic focus on growth, innovation, and market expansion. The companys strong cash position, debt-free status, and commitment to shareholder returns position it well for continued success in the infection prevention market.
| Metric | 2024 (£m) | 2025 (£m) | Change (£m) | Change (%) |
|---|---|---|---|---|
| Revenue | 41.9 | 46.5 | 4.6 | 11% |
| Gross Profit | 33.6 | 37.5 | 3.9 | 12% |
| Adjusted Pre-Tax Profit | 8.2 | 10.1 | 1.9 | 23% |
| Reported Pre-Tax Profit | 7.1 | 8.4 | 1.3 | 18% |
| Cash and Short-Term Investments | 11.8 | 12.8 | 1.0 | 8% |
| Debt | 0 | 0 | 0 | 0% |
Notes:
- Tristel PLC remains debt-free in both years.
- All financial figures are in millions of British Pounds (£m).